RPID RAPID MICRO BIOSYSTEMS, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1380106 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.1%
TTM net income YoY-16.1%
TTM EPS YoY-11.0%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-141.5%
Net margin-145.6%
FCF margin-114.8%
EBITDA margin-133.0%
Returns
ROE-141.6%
ROA-76.4%
ROIC (approx.)-135.2%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets69.6%
Debt / equity1.08x
Current ratio2.55x
Interest coverage-21.16x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $33.59M | $28.05M |
| R&D expense | $13.60M | $14.60M |
| SG&A expense | $22.75M | $21.95M |
| Operating income | -$47.39M | -$49.92M |
| Interest expense | $1.09M | $40,000 |
| Pretax income | -$47.08M | -$46.87M |
| Income tax | $40,000 | $22,000 |
| Net income | -$47.12M | -$46.89M |
| EBITDA | -$44.14M | -$46.56M |
| EPS (basic) | -1.05 | -1.08 |
| EPS (diluted) | -1.05 | -1.08 |
| Weighted avg. shares (diluted) | 44.68M | 43.58M |
| Balance sheet | ||
| Cash & equivalents | $20.03M | $17.28M |
| Short-term investments | $18.27M | $33.82M |
| Receivables | $3.13M | $7.52M |
| Inventory | $17.59M | $20.20M |
| Current assets | $61.17M | $80.92M |
| PP&E, net | $8.97M | $11.19M |
| Total assets | $74.85M | $98.17M |
| Current liabilities | $18.49M | $17.57M |
| Long-term debt | $18.90M | $0 |
| Total debt | $18.90M | $0 |
| Total liabilities | $41.65M | $22.82M |
| Shareholders' equity | $33.21M | $75.35M |
| Net debt | -$1.13M | -$17.28M |
| Cash flow statement | ||
| Operating cash flow | -$31.06M | -$44.15M |
| Capital expenditure | $850,000 | $1.36M |
| Free cash flow | -$31.91M | -$45.52M |
| Investing cash flow | $14.33M | $36.66M |
| Financing cash flow | $19.77M | $203,000 |
| Depreciation & amortization | $3.25M | $3.36M |
| Stock-based compensation | $4.03M | $3.87M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.